Abstract
Purpose
This study aimed to analyze the age-adjusted mortality rates (AAMR) per 100,000 for gynecological cancer-related deaths in the United States from 1999 to 2020. We compare trends by different demographic groups to identify significant disparities in these rates between populations within the United States.
Methods
The National Cancer Institute's Joinpoint Regression Program was used to calculate the average Annual Percent Change (AAPC) to identify trends over the study period using data from the CDC Wonder database, which comprises of demographic information for all causes of mortality in the United States from death certificate records.
Results
From 1999 to 2020, the African American population exhibited a significant downtrend (AAPC, -0.8% [95% CI, – 1.0% to – 0.6%]; p < 0.01), while the white population also demonstrated a notable downtrend (AAPC, – 1.0% [95% CI, – 1.2% to – 0.8%]; p < 0.01). Similarly, the AI/AN population experienced a decline (AAPC, – 1.6% [95% CI, – 2.4% to – 0.9%]; p < 0.01). The AAPI population did not observe a significant trend (AAPC, – 0.2% [95% CI, – 0.5% to 0.5%]; p = 0.127). In addition, the Hispanic/LatinX population experiencing a lower rate of decline compared to non-Hispanics (p = 0.025).
Conclusions
We found that the AI/AN population to observe the greatest downtrend in mortality rates, while the AAPI observed the least and that the African American population observed a smaller downtrend when compared to the white population. In addition, the Hispanic/LatinX community are significantly being underserved by developing therapies compared to the non-Hispanic/LatinX population. These findings provide valuable insights into the impact of gynecological cancers on specific demographic groups, emphasizing the urgency of targeted interventions to address disparities and improve outcomes.
Similar content being viewed by others
Data availability
The data used for this investigation uses publicly accessible data as provided in the results.
References
Bandera EV, Lee VS, Rodriguez-Rodriguez L, Powell CB, Kushi LH (2016) Racial/ethnic disparities in ovarian cancer treatment and survival. Clin Cancer Res 22(23):5909–5914. https://doi.org/10.1158/1078-0432.CCR-16-1119. (PubMed PMID: 27521449; PubMed Central PMCID: PMCPMC5135649)
Bogani G, Leone Roberti Maggiore U, Rossetti D, Ditto A, Martinelli F, Chiappa V et al (2019) Advances in laparoscopic surgery for cervical cancer. Crit Rev Oncol Hematol 143:76–80. https://doi.org/10.1016/j.critrevonc.2019.07.021
Bristow RE, Powell MA, Al-Hammadi N, Chen L, Miller JP, Roland PY et al (2013) Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst 105(11):823–832. https://doi.org/10.1093/jnci/djt065. (PubMed PMID: 23539755; PubMed Central PMCID: PMCPMC3691950)
Bristow RE, Chang J, Ziogas A, Campos B, Chavez LR, Anton-Culver H (2015) Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines. Obstet Gynecol 125(4):833–842. https://doi.org/10.1097/AOG.0000000000000643. (PubMed PMID: 25751200; PubMed Central PMCID: PMCPMC5167570)
Buskwofie A, David-West G, Clare CA (2020) A review of cervical cancer: incidence and disparities. J Natl Med Assoc 112(2):229–232. https://doi.org/10.1016/j.jnma.2020.03.002
Chung SK, Vargas DB, Chandler CS, Katugampola S, Veach DR, McDevitt MR et al (2023) Efficacy of HER2-Targeted Intraperitoneal (225)Ac alpha-pretargeted radioimmunotherapy for small-volume ovarian peritoneal carcinomatosis. J Nucl Med. https://doi.org/10.2967/jnumed.122.265095. (PubMed PMID: 37348919)
Cohen CM, Wentzensen N, Castle PE, Schiffman M, Zuna R, Arend RC et al (2023) Racial and ethnic disparities in cervical cancer incidence, survival, and mortality by histologic subtype. J Clin Oncol 41(5):1059–1068. https://doi.org/10.1200/JCO.22.01424
Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N (2022) Endometrial cancer. Lancet 399(10333):1412–1428. https://doi.org/10.1016/S0140-6736(22)00323-3. (PubMed PMID: 35397864)
Dedden SJ, Geomini P, Huirne JAF, Bongers MY (2017) Vaginal and Laparoscopic hysterectomy as an outpatient procedure: a systematic review. Eur J Obstet Gynecol Reprod Biol 216:212–223. https://doi.org/10.1016/j.ejogrb.2017.07.015
Elias KM, Guo J, Bast RC Jr (2018) Early detection of ovarian cancer. Hematol Oncol Clin North Am 32(6):903–914. https://doi.org/10.1016/j.hoc.2018.07.003. (PubMed PMID: 30390764; PubMed Central PMCID: PMCPMC6376972)
Guan LY, Lu Y (2018) New developments in molecular targeted therapy of ovarian cancer. Discov Med 26(144):219–229 (PubMed PMID: 30695681)
Gupta KK, Gupta VK, Naumann RW (2019) Ovarian cancer: screening and future directions. Int J Gynecol Cancer 29(1):195–200. https://doi.org/10.1136/ijgc-2018-000016. (PubMed PMID: 30640704)
Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19:335–351
Kim HJ, Fay MP, Yu B, Barrett MJ, Feuer EJ (2004) Comparability of segmented line regression models. Biometrics 60(4):1005–1014. https://doi.org/10.1111/j.0006-341X.2004.00256.x. (PubMed PMID: 15606421)
Kostov S, Watrowski R, Kornovski Y, Dzhenkov D, Slavchev S, Ivanova Y et al (2022) Hereditary gynecologic cancer syndromes - a narrative review. Onco Targets Ther 15:381–405. https://doi.org/10.2147/OTT.S353054
Kumar L, Harish P, Malik PS, Khurana S (2018) Chemotherapy and targeted therapy in the management of cervical cancer. Curr Probl Cancer 42(2):120–128. https://doi.org/10.1016/j.currproblcancer.2018.01.016. (PubMed PMID: 29530393)
Merkin SS, Phy JL, Sites CK, Yang D (2016) Environmental determinants of polycystic ovary syndrome. Fertil Steril 106(1):16–24. https://doi.org/10.1016/j.fertnstert.2016.05.011. (PubMed PMID: 27240194)
Methodology S (2016) Joinpoint regression program, version, 4, Applications Branch, Surveillance Research Program, National Cancer Institute., Bethesda, MD
Olawaiye AB, Cuello MA, Rogers LJ (2021) Cancer of the vulva: 2021 update. Int J Gynaecol Obstet 155(Suppl 1):7–18. https://doi.org/10.1002/ijgo.13881. (PubMed PMID: 34669204; PubMed Central PMCID: PMCPMC9298362)
Pan G, Liu Y, Shang L, Zhou F, Yang S (2021) EMT-associated microRNAs and their roles in cancer stemness and drug resistance. Cancer Commun (lond) 41(3):199–217. https://doi.org/10.1002/cac2.12138. (PubMed PMID: 33506604; PubMed Central PMCID: PMCPMC7968884)
Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J et al (2019) Risk factors for endometrial cancer: an umbrella review of the literature. Int J Cancer 145(7):1719–1730. https://doi.org/10.1002/ijc.31961. (PubMed PMID: 30387875)
Sawaya GF, Smith-McCune K, Kuppermann M (2019) Cervical cancer screening: more choices in 2019. JAMA 321(20):2018–2019. https://doi.org/10.1001/jama.2019.4595. (PubMed PMID: 31135834; PubMed Central PMCID: PMCPMC6656358)
Teoh D, Musa F, Salani R, Huh W, Jimenez E (2020) Diagnosis and management of adenocarcinoma in situ: a society of gynecologic oncology evidence-based review and recommendations. Obstet Gynecol 135(4):869–878. https://doi.org/10.1097/AOG.0000000000003761. (PubMed PMID: 32168211; PubMed Central PMCID: PMCPMC7098444)
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD et al (2018) Ovarian cancer statistics, 2018. CA Cancer J Clin 68(4):284–296. https://doi.org/10.3322/caac.21456. (PubMed PMID: 29809280; PubMed Central PMCID: PMCPMC6621554)
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP et al (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 147(8):573–577. https://doi.org/10.7326/0003-4819-147-8-200710160-00010. (PubMed PMID: 17938396)
Yuan Y, Cai X, Shen F, Ma F (2021) HPV post-infection microenvironment and cervical cancer. Cancer Lett 497:243–254. https://doi.org/10.1016/j.canlet.2020.10.034. (PubMed PMID: 33122098)
Zapardiel I, Rajaram S, Piovano E, Petrillo M (2015) Challenges in gynecological cancer: biology, diagnosis, surgical, and medical treatment. Biomed Res Int 2015:787080. https://doi.org/10.1155/2015/787080. (PubMed PMID: 26185763; PubMed Central PMCID: PMCPMC4491547)
Funding
None.
Author information
Authors and Affiliations
Contributions
SD: conceptualization, methodology, software, data curation, writing- original draft preparation, visualization, and investigation. OS: writing, reviewing and editing. MM: methodology, software, data curation. SK: reviewing and editing, supervision.
Corresponding author
Ethics declarations
Conflict of interest
No conflict of interest to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Doddi, S., Salichs, O., Mushuni, M. et al. Demographic disparities in trend of gynecological cancer in the United States. J Cancer Res Clin Oncol 149, 11541–11547 (2023). https://doi.org/10.1007/s00432-023-05030-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-023-05030-4